AGAP2 antisense RNA 1 (AGAP2-AS1)

AGAP2 antisense RNA 1 (AGAP2-AS1) is a long non-coding RNA (lncRNA, 1567 nucleotides in length), transcribed from the chromosome 12q14.1 locus. Unlike protein-coding genes, AGAP2-AS1 does not code for a protein but regulates gene expression by interacting with chromatin-modifying enzymes (such as components of PRC2: EZH2, SUZ12, EED) and functioning as a competing endogenous RNA ("miRNA sponge"). AGAP2-AS1 is frequently overexpressed in a variety of cancers, where it promotes tumor progression by enhancing cell proliferation, suppressing apoptosis, and facilitating invasion and migration, mainly through epigenetic mechanisms and miRNA sequestration. It is associated with poor clinical prognosis, and its upregulation correlates with tumor aggressiveness. Although not yet a direct drug target, AGAP2-AS1 is actively studied as a potential therapeutic target and biomarker in oncology and may have relevance in other diseases such as psoriasis, pre-eclampsia, and systemic sclerosis[1][2][5][6].

Other names

LOC100130776PUNISHERAGAP2-AS1

Epigenetic regulation by binding to chromatin modifiers (e.g., PRC2 complex: EZH2, SUZ12, EED); miRNA sponging (ceRNA mechanism): binds and sequesters microRNAs such as miR-424-5p, miR-16-5p, miR-15a/b-5p, miR-9-5p, among others, thereby upregulating oncogenic pathways; Scaffold for protein complexes involved in gene silencing (e.g., LSD1, WDR5, AGO2)